Armata Pharmaceuticals (ARMP) director receives grant of 25,640 stock options

Rhea-AI Filing Summary

Armata Pharmaceuticals director Jules Haimovitz received a grant of stock options to acquire 25,640 shares of common stock. The options have an exercise price of 11.61 per share and expire on March 9, 2036. They will vest in full on March 9, 2027, subject to continuous service through that date. Following this award, Haimovitz holds 25,640 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haimovitz Jules

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		25,640		(1)	03/09/2036	Common Stock	25,640	$0.00	25,640	D

Explanation of Responses:

1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

	/s/ Jules Haimovitz	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report for Jules Haimovitz?

Armata Pharmaceuticals reported that director Jules Haimovitz received a grant of 25,640 stock options. These options give him the right to buy common shares at a set exercise price and represent a compensation-related award rather than an open-market share purchase or sale.

What are the key terms of Jules Haimovitz’s new stock options at Armata (ARMP)?

Jules Haimovitz was granted 25,640 stock options with an exercise price of 11.61 per share. The options relate to common stock, are held directly, and provide the right to acquire the same number of underlying shares if exercised in the future.

When do the newly granted Armata (ARMP) stock options to Jules Haimovitz vest and expire?

The stock options granted to Jules Haimovitz will vest in full on March 9, 2027, subject to continuous service. They carry an expiration date of March 9, 2036, giving a long-term window during which he may choose to exercise the options after vesting.

Is Jules Haimovitz buying or selling Armata Pharmaceuticals (ARMP) shares in this Form 4?

The Form 4 shows an acquisition via a grant of 25,640 stock options, not an open-market buy or sale of existing shares. The transaction is coded as a grant or award, reflecting equity compensation rather than trading activity in Armata’s common stock.

How many Armata (ARMP) stock options does Jules Haimovitz hold after this award?

After the reported grant, Jules Haimovitz holds 25,640 stock options directly. Each option corresponds to one share of Armata Pharmaceuticals common stock, giving him potential future ownership if he exercises the options after they vest and before expiration.